239 related articles for article (PubMed ID: 26112458)
1. Aggressive thyroid cancer: targeted therapy with sorafenib.
Corrado A; Ferrari SM; Politti U; Mazzi V; Miccoli M; Materazzi G; Antonelli A; Ulisse S; Fallahi P; Miccoli P
Minerva Endocrinol; 2017 Mar; 42(1):64-76. PubMed ID: 26112458
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib and thyroid cancer.
Fallahi P; Ferrari SM; Santini F; Corrado A; Materazzi G; Ulisse S; Miccoli P; Antonelli A
BioDrugs; 2013 Dec; 27(6):615-28. PubMed ID: 23818056
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib in the treatment of thyroid cancer.
Ferrari SM; Politti U; Spisni R; Materazzi G; Baldini E; Ulisse S; Miccoli P; Antonelli A; Fallahi P
Expert Rev Anticancer Ther; 2015; 15(8):863-74. PubMed ID: 26152651
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib for the treatment of thyroid cancer: an updated review.
Krajewska J; Handkiewicz-Junak D; Jarzab B
Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
[TBL] [Abstract][Full Text] [Related]
5. Sorafenib: targeting multiple tyrosine kinases in cancer.
Hasskarl J
Recent Results Cancer Res; 2014; 201():145-64. PubMed ID: 24756790
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib: 10 years after the first pivotal trial.
Gadaleta-Caldarola G; Infusino S; Divella R; Ferraro E; Mazzocca A; De Rose F; Filippelli G; Abbate I; Brandi M
Future Oncol; 2015; 11(13):1863-80. PubMed ID: 26161924
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status.
Broecker-Preuss M; Müller S; Britten M; Worm K; Schmid KW; Mann K; Fuhrer D
BMC Cancer; 2015 Mar; 15():184. PubMed ID: 25879531
[TBL] [Abstract][Full Text] [Related]
8. Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Smolle E; Taucher V; Petru E; Haybaeck J
Anticancer Res; 2014 Apr; 34(4):1519-30. PubMed ID: 24692678
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib in metastatic thyroid cancer: a systematic review.
Thomas L; Lai SY; Dong W; Feng L; Dadu R; Regone RM; Cabanillas ME
Oncologist; 2014 Mar; 19(3):251-8. PubMed ID: 24563075
[TBL] [Abstract][Full Text] [Related]
10. Selective use of sorafenib in the treatment of thyroid cancer.
Pitoia F; Jerkovich F
Drug Des Devel Ther; 2016; 10():1119-31. PubMed ID: 27042004
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis.
Shen CT; Qiu ZL; Luo QY
Endocr Relat Cancer; 2014 Apr; 21(2):253-61. PubMed ID: 24302666
[TBL] [Abstract][Full Text] [Related]
12. Novel molecular targeted therapies for refractory thyroid cancer.
Perez CA; Santos ES; Arango BA; Raez LE; Cohen EE
Head Neck; 2012 May; 34(5):736-45. PubMed ID: 21544895
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.
Gridelli C; Maione P; Del Gaizo F; Colantuoni G; Guerriero C; Ferrara C; Nicolella D; Comunale D; De Vita A; Rossi A
Oncologist; 2007 Feb; 12(2):191-200. PubMed ID: 17296815
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma.
Blair HA; Plosker GL
Target Oncol; 2015 Mar; 10(1):171-8. PubMed ID: 25742918
[TBL] [Abstract][Full Text] [Related]
15. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment.
Strumberg D
Drugs Today (Barc); 2005 Dec; 41(12):773-84. PubMed ID: 16474853
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid.
Savvides P; Nagaiah G; Lavertu P; Fu P; Wright JJ; Chapman R; Wasman J; Dowlati A; Remick SC
Thyroid; 2013 May; 23(5):600-4. PubMed ID: 23113752
[TBL] [Abstract][Full Text] [Related]
17. (Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Schneider TC; Kapiteijn E; van Wezel T; Smit JWA; van der Hoeven JJM; Morreau H
BMC Cancer; 2016 Jan; 16():31. PubMed ID: 26786320
[TBL] [Abstract][Full Text] [Related]
18. The adverse effects of sorafenib in patients with advanced cancers.
Li Y; Gao ZH; Qu XJ
Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):216-21. PubMed ID: 25495944
[TBL] [Abstract][Full Text] [Related]
19. The discovery and development of sorafenib for the treatment of thyroid cancer.
White PT; Cohen MS
Expert Opin Drug Discov; 2015 Apr; 10(4):427-39. PubMed ID: 25662396
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer.
Yi H; Ye X; Long B; Ye T; Zhang L; Yan F; Yang Y; Li L
Cancer Biother Radiopharm; 2017 Jun; 32(5):176-183. PubMed ID: 28622037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]